Full-year EPS guidance raised to greater than $4.80 from $3.40
Centene delivered a strong Q2 2026 with EPS of $2.51, raising full-year guidance significantly to >$4.80. The company saw outperformance in Marketplace, Medicare PDP, and MA, with management focusing on margin restoration and AI-led efficiency. Medicaid attrition is running higher than expected, but rate improvements are offsetting the acuity impact. FY2026 EPS guidance raised to >$4.80 from >$3.40, driven by Marketplace margin recovery and strong PDP performance.
Buzzberg readFull-year EPS guidance raised to greater than $4.80 from $3.40Centene delivered a strong Q2 2026 with EPS of $2.51, raising full-year guidance significantly to >$4.80. The company saw outperformance in Marketplace, Medicare PDP, and MA, with management focusing on margin restoration and AI-led efficiency. Medicaid attrition is running higher than expected, but rate improvements are offsetting the acuity impact. FY2026 EPS guidance raised to >$4.80 from >$3.40, driven by Marketplace margin recovery and strong PDP performance.Read full analysisCollapse analysis
Centene delivered a strong Q2 2026 with EPS of $2.51, raising full-year guidance significantly to >$4.80. The company saw outperformance in Marketplace, Medicare PDP, and MA, with management focusing on margin restoration and AI-led efficiency. Medicaid attrition is running higher than expected, but rate improvements are offsetting the acuity impact. FY2026 EPS guidance raised to >$4.80 from >$3.40, driven by Marketplace margin recovery and strong PDP performance.
Marketplace pre-tax margin guidance raised to 4.5%-5% from 3%, supported by favorable risk adjustment and moderating trend.
Medicaid membership expected to decline 8-9% in 2026, with higher acuity in the expansion population offset by better-than-expected 7-1 rate increases.
Medicare PDP margin guidance raised to >3% for 2026, reflecting stable IRA impact and favorable drug trend.
Revenue$44.375B
-11% QoQ
EPS$2.51
-26% QoQ
Gross margin10.4%
reported
Op margin3.1%
reported
What changed this quarter
01
Guidance
Full-year EPS guidance raised to greater than $4.80 from $3.40
Guidance tone
02
Marketplace
Marketplace margin expected at 4.5%-5% for 2026
FY2026 EPS guidance raised to >$4.80 from >$3.40, driven by Marketplace margin recovery and strong PDP performance.
03
Margins
PDP margin expectation raised to greater than 3%
Reported gross margin was 10.4%, reinforcing the quarter's better-than-guided profitability.
04
Medicaid
Medicaid enrollment decline expected at 8-9% for 2026
Medicaid membership expected to decline 8-9% in 2026, with higher acuity in the expansion population offset by better-than-expected 7-1 rate increases.
AI, capex & demand read
AI
Platform & monetization
Centene is shifting AI strategy from individual use cases to foundational capabilities like trusted data products and dynamic context management, with a focus on ROI and scalability. Early AI use cases, such as invoice review in legal, are delivering savings, and the company sees long-term differentiation from proprietary data and context.
Demand
Bookings & conversion
Management raised FY2026 EPS guidance significantly and expressed confidence in margin restoration across business lines, pointing to strong execution and favorable market dynamics.
Capex
Investment and capacity
No explicit capital expenditure or capacity investment details were provided, but the company is investing in AI and technology to drive efficiencies, with an expected $480 million midpoint of SG&A costs in 2026 related to workforce and enterprise optimization.
Tone · Confident
Management expressed strong confidence in improved financial guidance, robust execution across business segments, and strategic positioning for future margin restoration, despite acknowledged headwinds like Medicaid enrollment attrition and OB-3 implementation.
Supply-chain alpha
A1
Medicaid membership attrition is accelerating, with full-year guidance now expecting a decline of 8-9% versus prior 6%, driven by state-level program changes and OB-3 preparation, leading to a slight uptick in acuity that management is absorbing.
“We expect full-year Medicaid membership to be down 8-9% compared to 12-31-25 versus our prior view of being down 6%.”
The 2025 marketplace risk adjustment reconciliation benefited the company by $180 million in Q2, and management now expects a 'meaningful receivable' in 2026, indicating a favorable position relative to the market risk pool.
“we received favorable development on our final 2025 CMS risk adjustment reconciliation to the tune of $180 million in the quarter.”